Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference
Arcutis Biotherapeutics (ARQT) has scheduled its third quarter 2024 financial results announcement and business update for Wednesday, November 6, 2024, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day. Additionally, Arcutis will participate in Guggenheim's Inaugural Healthcare Innovation Conference with a fireside chat scheduled for Monday, November 11 at 3:30 p.m. ET. Both events will be accessible through webcasts in the 'Events' section of the company's website, with archived replays available afterward.
Arcutis Biotherapeutics (ARQT) ha programmato l'annuncio dei risultati finanziari del terzo trimestre 2024 e un aggiornamento aziendale per mercoledì 6 novembre 2024, dopo la chiusura del mercato. L'azienda ospiterà una conferenza telefonica e una trasmissione in diretta alle 16:30 ET nella stessa giornata. Inoltre, Arcutis parteciperà alla Conferenza Inaugurale sull'Innovazione Sanitaria di Guggenheim con una chiacchierata informale fissata per lunedì 11 novembre alle 15:30 ET. Entrambi gli eventi saranno accessibili tramite webcast nella sezione 'Eventi' del sito web dell'azienda, con repliche archiviate disponibili successivamente.
Arcutis Biotherapeutics (ARQT) ha programado el anuncio de sus resultados financieros para el tercer trimestre de 2024 y una actualización empresarial para el miércoles 6 de noviembre de 2024, después del cierre del mercado. La compañía realizará una llamada de conferencia y una transmisión en vivo a las 4:30 p.m. ET el mismo día. Además, Arcutis participará en la Conferencia de Innovación en Salud Inaugural de Guggenheim con una charla junto a la chimenea programada para el lunes 11 de noviembre a las 3:30 p.m. ET. Ambos eventos estarán disponibles a través de retransmisiones en la sección 'Eventos' del sitio web de la compañía, con repeticiones archivadas disponibles posteriormente.
Arcutis Biotherapeutics (ARQT)는 2024년 3분기 재무 결과 발표 및 사업 업데이트를 2024년 11월 6일 수요일, 시장 종료 후에 예정하고 있습니다. 회사는 같은 날 오후 4시 30분(ET)에 컨퍼런스 콜 및 웹캐스트를 개최할 예정입니다. 또한, Arcutis는 구겐하임의 혁신 의료 회의에 참여하며, 11월 11일 월요일 오후 3시 30분(ET)에 파이어사이드 채팅이 예정되어 있습니다. 두 이벤트는 회사 웹사이트의 '이벤트' 섹션에서 웹캐스트를 통해 접근 가능하며, 이후 아카이브된 재생도 제공될 예정입니다.
Arcutis Biotherapeutics (ARQT) a prévu l'annonce de ses résultats financiers pour le troisième trimestre 2024 et une mise à jour des activités pour le mercredi 6 novembre 2024, après la clôture du marché. L'entreprise organisera une conférence téléphonique et une diffusion en direct à 16h30 ET le même jour. De plus, Arcutis participera à la Conférence Inaugurale sur l'Innovation en Santé de Guggenheim, avec une discussion informelle prévue pour le lundi 11 novembre à 15h30 ET. Les deux événements seront accessibles par le biais de diffusions en direct dans la section 'Événements' du site web de l'entreprise, avec des rediffusions archivées disponibles par la suite.
Arcutis Biotherapeutics (ARQT) hat die Bekanntgabe der finanziellen Ergebnisse für das dritte Quartal 2024 und ein Geschäfts-Update für Mittwoch, den 6. November 2024, nach Marktschluss geplant. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten. Darüber hinaus wird Arcutis an der Guggenheim's Inaugural Healthcare Innovation Conference teilnehmen, mit einem Fireside-Chat, der für Montag, den 11. November um 15:30 Uhr ET geplant ist. Beide Veranstaltungen werden über Webcasts im Bereich 'Events' auf der Unternehmenswebsite zugänglich sein, mit anschließend verfügbaren Archivaufzeichnungen.
- None.
- None.
- Quarterly investor conference call and webcast is scheduled for Wednesday, November 6 at 4:30 p.m. ET
- Arcutis management will also participate in the Guggenheim Securities Healthcare Innovation Conference in November
WESTLAKE VILLAGE, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report third quarter 2024 financial results and provide a business update on Wednesday, November 6, 2024 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:30 p.m. ET.
A live webcast of the call and the presentation materials will be available on the “Events” section of the Company’s website. An archived replay of the webcast will be available in the same location following the conference call.
Arcutis also announced its participation for an upcoming investor conference. Details for the company’s participation are as follows:
- Guggenheim’s Inaugural Healthcare Innovation Conference
Fireside Chat Date/Time: Monday, November 11 at 3:30 p.m. ET
A live webcast for this event may be accessed at the “Events” section of the Company’s website. An archived replay of the fireside chat will be available in the same location following the event.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including three FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.
Forward-Looking Statements
Arcutis cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, and the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 27, 2024, as well as any subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Latha Vairavan, Vice President, Finance and Corporate Controller
ir@arcutis.com
FAQ
When will Arcutis (ARQT) report Q3 2024 earnings?
What time is Arcutis (ARQT) Q3 2024 earnings call?
When is Arcutis (ARQT) presenting at the Guggenheim Healthcare Innovation Conference?
